Advances in the Treatment of Advanced Non-Small Cell Lung Cancer

• 作者: Juncheng Guo Min Guo Xianshan Chen
• 来源期刊: 肺癌(英文)
• 学科: 医学
• 关键词: Non-Small Cell Lung Cancer DRUGS TARGETED CHEMOTHERAPY
• 年，卷（期）: 2020,（2）
• 页码范围: 30-40
• 页数: 11页
• 分类号: R73

摘要

In recent years, the incidence of lung adenocarcinoma has been increasing, </span><span style="font-family:Verdana;">and now it has become the largest type of non-small cell lung cancer (NSCLC)</span><span style="font-family:Verdana;">. Currently, treatment of advanced NSCLC consists of several modalities: systemic chemotherapy, local radiation therapy, and targeted therapy (including most recently immunotherapy). In the past decade, the discovery of new mo</span><span style="font-family:Verdana;">lecular subtypes, the search for tumor driver gene mutations, the developmen</span><span style="font-family:Verdana;">t </span><span style="font-family:Verdana;">of targeted molecular targeted drugs, or targeted therapy to suppress tumor angioge</span><span style="font-family:Verdana;">nesis and regulate tumor immune response have been the main directio</span><span style="font-family:Verdana;">ns of NSCLC research and clinical diagnosis and treatment. At present, platinum-based chemotherapy is widely used in NSCLC patients clini</span><span style="font-family:Verdana;">cally. Platinum-based chemotherapy drugs can effectively prolong the survival time of patients and improve their quality of life, but the incidence of adverse reactions is still high. Therefore, it is necessary to find a drug that can improve the efficacy of patients and reduce the adverse reactions of platinum chemotherapy drugs to NSCLC patients.